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DNA sequencing‑based measurable residual disease (MRD) detection has shown to be clinically 
relevant in AML. However, the same methodology cannot be applied to fusion gene‑driven subtypes 
of AML such as core‑binding factor AML (CBF‑AML). Here in this study, we evaluated the effectiveness 
of using DNA and RNA sequencing in MRD detection and in tracking clonal dynamics in CBF‑AML. 
Using RNA‑seq, we were able to quantify expression levels of RUNX1‑RUNX1T1 and CBFB‑MYH11 
at diagnosis and their levels of reduction during remission (P < 6.3e−05 and P < 2.2e−13). The level of 
reduction of RUNX1-RUNX1T1 as measured by RNA‑seq and qPCR were highly correlated  (R2 = 0.74, 
P < 5.4e−05). A decision tree analysis, based on 3‑log reduction of RUNX1‑RUNX1T1 and cKIT‑D816mut 
at diagnosis, stratified RUNX1-RUNX1T1 AML patients into three subgroups. These three subgroups 
had 2‑year overall survival rates at 87%, 74%, and 33% (P < 0.08) and 2‑year relapse incidence 
rates at 13%, 42%, and 67% (P < 0.05). On the other hand, although low residual allelic burden was 
common, it was not associated with long‑term outcome, indicating that mutation clearance alone 
cannot be interpreted as MRD‑negative. Overall, our study demonstrates that the clinical utility of 
RNA sequencing as a potential tool for MRD monitoring in fusion gene‑driven AML such as RUNX1-
RUNX1T1 AML.
Leveraging on advances in next generation sequencing (NGS) technologies, a wide range of heterogenous genetic 
baseline characteristics has been discovered in acute myeloid leukemia (AML)1,2. Recent studies showed that tar-
geted DNA sequencing-based measurable residual disease (MRD) detection is feasible in  AML3–7. However, the 
weakness of targeted DNA sequencing based MRD detection is that it is not efficient to reliably track breakpoints 
of gene rearrangements using a targeted panel. The prevalence of gene rearrangement-driven AML is about 30%8. 
For instance, gene rearrangements affecting core binding factor (CBF) complex, RUNX1-RUNX1T1/t(8;21) or 
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CBFB-MYH11/inv(16) are found in about 15% of AML patients (hereafter referred to as t(8;21) and inv(16) AML, 
respectively)9. Compared with other AML subtypes, CBF-AML is considered as a favourable risk subgroup due 
to favourable long-term outcomes following high-dose cytarabine-based  chemotherapy8,10. However, up to 40% 
of CBF-AML patients still  relapse11–13. As a post-remission monitoring of CBF-AML, a quantitative PCR (qPCR) 
assay targeting t(8;21) and inv(16) at remission can identify patients at high risk of relapse and has become a 
routine  procedure14–16. Recently, a study by Dillon et al. demonstrated that MRD assessment using targeted RNA 
sequencing is feasible and correlates well with qPCR  assays17.
While qPCR is highly sensitive and sequence-specific, it can only test a limited set of fusion events, making it 
neither scalable nor being used as a discovery tool. Thus, multiple tests have to be performed at diagnosis in order 
to characterize appropriate MRD targets to monitor post-treatment. In addition, standardization procedures 
make it challenging to compare qPCR results from different institutions and hospitals. On the other hand, RNA 
sequencing (RNA-seq) is scalable to quantify multiple targets in a single assay. In addition, it can also simulta-
neously quantify transcript expression, discover novel fusion transcripts, and even detect somatic mutations. 
Considering these advantages of RNA-seq and reductions in sequencing costs in recent years, we hypothesized 
that a single assay of RNA-seq can be utilized not only to detect mutations and fusion transcripts at diagnosis, 
but also quantify their reduction level at complete remission (CR).
Here we describe a study to evaluate DNA and RNA sequencing on longitudinal samples taken at diagnosis 
and at CR, as potential MRD detection tools for post-remission monitoring of CBF-AML. With this approach, 
we hoped to gain additional insights on how NGS can be applied to monitor MRD in CBF-AML, as well as reveal 
comprehensive dynamics of somatic mutations, transcripts, and gene rearrangements from diagnosis till CR. 
To address these questions, we conducted DNA sequencing (DNA-seq) on 223 DNA samples collected from 87 
patients including 62 patients with t(8;21) and 25 patients with inv(16) taken at time points including diagnosis, 
CR, and relapse. For a subset of patients with available samples, we conducted RNA-seq on 90 samples consisted 
of 42 pairs of diagnosis-CR samples as well as 6 relapse samples.
The main goal of current study was to assess whether residual genetic alterations including primary (i.e. 
subtype-defining gene rearrangements) and secondary (i.e. single nucleotide variants and short indels) lesions 
at CR can be quantified using RNA and DNA-seq and are clinically relevant. Most notably, current study dem-
onstrates how RNA-seq can be utilized to track gene rearrangements during remission and serves as a proof-
of-concept study for RNA seq-based MRD detection for gene rearrangement-driven hematologic malignancies.
Materials and methods
Patient cohorts and acquisition of samples. Eighty-seven patients with newly diagnosed CBF-AML 
from January 2003 to September 2015 were included in this study. All patients had an Eastern Cooperative 
Oncology Group (ECOG) performance status ≤ 2 at the time of diagnosis. Patients treated with investigational 
drugs before induction therapy were excluded. Treatment and response assessments are summarized in Sup-
plementary Information. Samples for NGS were obtained at the time of initial diagnosis (n = 87 and n = 42 for 
DNA and RNA-seq), CR (n = 53/87 and n = 42/42 for DNA and RNA-seq), and relapse (n = 15/87 and n = 6/42 
for DNA and RNA-seq). CR samples were obtained either at day 28 (n = 45/53 and n = 34/42 for DNA and RNA-
seq) or day 56 after re-induction (n = 8/53 and n = 8/42 for DNA and RNA-seq). Among 155 samples subjected 
for DNA sequencing, 151 samples were taken from bone-marrow (BM) and other 4 samples were taken from 
peripheral blood (PB). For patients with available serial samples, 90 samples (42 + 42 + 6) from 42 patients were 
also subjected to RNA-seq. All patient samples were collected after obtaining informed consent. Among 90 
samples subjected for RNA sequencing, 86 samples were taken from BM and other 4 samples were taken from 
PB. All experiments and methods were carried out in accordance with relevant guidelines and regulations. This 
study was approved by the institutional ethics review boards at Chonnam National University Hwasun Hospital 
and Severance Hospital, Republic of Korea (CNUHH-2015-118).
Sample preparation and next generation sequencing. BM/PB samples used in this study were pro-
spectively procured and banked. After DNA isolation and library preparation, all samples were subjected to 
targeted sequencing. Targeted gene panel was constructed using a custom Agilent Sureselect design, covering 
exonic regions of 83 genes (Table S1 and Table S2). The gene list for targeted sequencing was compiled from our 
previous studies as well as large-scale mutation profiling studies on AML and  MDS1,2,18,19. For RNA-seq, the total 
RNA was extracted from BM/PB mononuclear cells using the RNeasy mini kit (Qiagen, Germany). Total RNA 
concentration was calculated by Quant-IT RiboGreen (Invitrogen, Carlsbad, CA, USA). To assess the integrity 
of the total RNA, samples were run on the TapeStation RNA screentape (Agilent Technologies, Santa Clara, CA, 
USA). A total of 100 ng of total RNA was subjected to a sequencing library construction using a TruSight RNA 
Pan-Cancer Panel (1385 genes) (Illumina, Inc., San Diego, CA USA) according to the manufacturer’s protocols. 
Both DNA and RNA samples were multiplexed and sequenced using an Illumina HiSeq 2500 (Illumina, San 
Diego, California, USA).
Sequencing metrics can be found in Table S3 (DNA-seq) and Table S4 (RNA-seq) and all sequencing data 
have been deposited at the European Nucleotide Archive (Accession: PRJEB25960 for DNA-seq and PRJEB27973 
for RNA-seq). The mean on-target coverage for 223 DNA samples was 1,645.1X. RNA sequencing of 90 samples 
yielded an average of 3.6 million reads (range 2.8–4.5 M) with an average 86.9% mapping rate (range 83.4–90.5%). 
Read processing and variant calling procedures for DNA-seq data were performed as in our previous study with 
minor  modifications19. Detailed methods on variant calling, RNA-seq read processing, transcript quantification, 
differentially expressed gene analyses and, fusion transcript discovery in diagnostic samples and its tracking in 
CR samples are provided in the Supplementary Information.
3
Vol.:(0123456789)
Scientific Reports |        (2020) 10:20119  | https://doi.org/10.1038/s41598-020-76933-2
www.nature.com/scientificreports/
Statistical analysis. Patient characteristics were summarized using descriptive statistics. Categorical vari-
ables were analyzed using a Chi-square test and comparison of continuous variables was performed using the 
Student’s t-test. The overall survival (OS) was defined as the time of diagnosis until death from any cause, which 
was analyzed using the Kaplan–Meier method. The groups were then compared using the log-rank test. The 
cumulative incidence of relapse was calculated using the Gray method, considering death without relapse as a 
competing risk. Non-relapse mortality was defined as any death while in remission with relapse as a competing 
risk and was assessed with the Gray’s test. The prognostic impact of risk factors on OS was determined using the 
Cox proportional hazard model. Fine-Gray proportional hazard regression with competing events were used to 
identify risk factors for relapse. P-values of less than 0.05 were considered significant. R statistical software 3.1.3 
(the R foundation for Statistical Computing, Vienna, Austria; available at https ://www.r-proje ct.org) and EZR 
(version 1.33) were used to perform statistical analyses and generate all  figures20.
Results
Patient characteristics and treatment outcomes. Among the 87 patients with newly diagnosed CBF-
AML, 62 patients were t(8;21) AML and 25 were inv(16) AML. The median age of the patients was 44 years 
(range 16–85 years) and 50 patients (57%) were male. Induction chemotherapy was administered for 76 out of 
87 (87%) patients. CR was achieved in 73 out of 76 patients (96%). The CR rate was 96% in both t(8;21) AML 
(n = 49/51) and inv(16) AML (n = 24/25). Three patients who failed to achieve CR died of treatment-related mor-
tality (n = 2) or disease progression (n = 1). Post-remission therapy with high dose cytarabine was administered 
at CR. The patient characteristics are summarized in Table 1.
Targeted DNA sequencing reveals mutation profiles at baseline and their clinical relevance in 
CBF‑AML. At diagnosis, we detected 166 mutations in 79 patients (n = 79/87, 90.8%) (Fig. 1 and Table S5). 
The 166 mutations consisted of 120 nonsynonymous single nucleotide variants (SNVs), 21 frameshift insertions, 
6 frameshift deletions, 5 non-frameshift insertions, 5 splicing events, 5 stop-gain SNVs, 2 non-frameshift dele-
tions, and 2 synonymous SNVs. The median number of mutations per patient was 2 (range 1–7). Among the 83 
targeted genes, 33 genes were mutated in at least one patient, and 18 genes were recurrently mutated. Notably, 
KIT (n = 34/87, 39%), NRAS (n = 29/87, 33%), ASXL2 (n = 12/87, 14%), and KRAS (n = 11/87, 13%) were fre-
quently mutated. Frequencies of mutation occurrence within targeted gene panel between two subtypes of CBF-
AML, irrespective of genes, were comparable (93.5% in t(8;21) AML and 88% in inv(16) AML, p < 0.29). When 
grouped by associated biological pathways, genes associated with signaling pathways (n = 70/87, 80%), chro-
matin modifiers (n = 19/87, 22%) and, the cohesin complex (n = 13/87, 15%) were mutated in more than 10% 
of the cohort and frequencies of mutations in RAS (KRAS or NRAS), chromatin modifiers (including ASXL2) 
and, cohesin complex were significantly different between the two subtypes of CBF-AML (P < 0.002, P < 0.01, 
and P < 0.02, respectively, Figure S1). In particular, members of cohesin complex and chromatin modifiers were 
nearly exclusively mutated in t(8;21) AML.
We performed survival analyses to investigate association of somatic mutation with patient outcome (n = 76/87 
after excluding the patients who did not receive chemotherapy) (Table S6). In univariate analysis, KIT-D816mut 
Table 1.  Baseline clinical and genetic characteristics of 87 core binding factor acute myeloid leukemia patients 
enrolled in this study. CBF-AML core binding factor acute myeloid leukemia, WBC white blood cell, CR 
complete remission.
No. (%) CBF-AML RUNX1-RUNX1T1 CBFB-MYH11 P
Number of patients 87 62 25
Age, median years (range) 44 (16–85) 43 (16–85) 47 (20–68) 0.55
Gender
Male 50 (57) 37 (60) 13 (52) 0.68
Female 37 (43) 25 (40) 12 (48)
WBC, × 109/L, median (range) 16.9 (1.0–201.8) 10.4 (1.0–201.8) 40.1 (2.7–163.3) 0.52
Mutations at baseline
KIT 34 (39) 28 (45) 6 (24) 0.11
D816 19 (22) 16 (26) 3 (12) 0.26
N822 13 (15) 13 (21) 0 0.02
RAS 36 (41) 19 (31) 17 (68)  < 0.01
NRAS 29 (33) 16 (26) 13 (52) 0.04
KRAS 11 (13) 5 (8) 6 (24) 0.10
ASXL2 12 (14) 12 (19) 0 0.03
Remission induction therapy 76 (87) 51 (82) 25 (100) 0.17
Achievement of CR, n = 76 73/76 (96) 49/51 (96) 24/25 (96) 1.00
Relapse, n = 73 19/73 (26) 13/49 (27) 6/24 (25) 1.00
Death 28 (37) 25 (40) 10 (40) 1.00
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was identified as an adverse prognostic factor for OS (Hazard ratio (HR) 2.31, 95% confidence interval (CI) 
1.04–5.14, P = 0.035). Three-year OS rate was inferior in KIT-D816mut group (47.1 ± 12.9%) to KIT-D816wt group 
(68.6 ± 6.4%; P = 0.035). In terms of CIR (cumulative incidence of relapse), KIT-D816mut was an adverse factor for 
CIR (HR 2.76 [1.06–7.15], P = 0.04), while mutations in RAS (NRAS or KRAS) was favorable for CIR (HR 0.13 
[0.03–0.56], P = 0.01). Three-year CIR was higher in KIT-D816mut group (43.8 ± 12.1%) than KIT-D816wt group 
(22.0 ± 5.6%; P = 0.035). CIR was lower in RASmut subgroup than RASwt (6.4 ± 4.5% vs. 41.9 ± 7.8%; P = 0.001), 
while NRM (non-relapse mortality) was higher in RASmut subgroup (22.8 ± 7.5% vs. 7.3 ± 4.2%; p = 0.001). 
Thus the 3-year OS rate was not different between the groups of RASmut and RASwt (70.0 ± 8.3% vs. 59.0 ± 8.0%; 
P = 0.999). Overall, KIT-D816mut was the only adverse prognostic mutation for OS.
Longitudinal tracking of somatic mutations from diagnosis to remission and their clinical rel‑
evance. Taking advantage of samples taken at diagnosis and at CR, we assessed whether allelic burden at 
CR is clinically relevant. Among the 53 patients with available CR samples, 49 patients carried 99 mutations 
at diagnosis. Overall, 99 mutations showed mean reduction at CR with mean reduction rate of 99.1% (ranges 
from 86.2% to 100%, p < 0.0001). Out of 99 mutations, 53 mutations were cleared at CR (i.e. no reads supporting 
the variant allele) (Fig. 2a). The 46 detectable mutations at CR from 32 patients were commonly located in KIT 
(n = 13), NRAS (n = 8), and KRAS (n = 3). Mutations with higher VAFs at diagnosis are more likely to be detected 
at CR (mean VAF 27.4% for mutations detectable at CR vs. 17.8% for mutations cleared at CR, p = 0.001). To 
estimate mutation-like sequencing errors, we computed the frequency of mutation-like nucleotide changes in 
CR samples from patients who did not have the mutation in their diagnosis specimens. Overall, we observed 
that median mutation-like error rate is 0.008% in our data (interquartile range 0.004–0.013%). We then inves-
tigated whether the mutation clearance at CR is associated with subsequent occurrence of relapse (Fig.  2b). 
Figure 1.  Spectrum of somatic mutation in 87 CBF-AML patients at initial diagnosis (n = 87). Targeted 
sequencing revealed 166 mutations at initial diagnosis of CBF-AML (62 t(8;21) AML and 25 inv(16) AML). 
The cohort is separated by their subtype of CBF-AML. inv(16) AML patients are shown on the left and t(8;21) 
AML patients are shown on the right. Each column indicates a single patient as well as each row represents a 
gene. Intensity of a cell in the heatmap on the top shows the relative level of VAF. In the heatmap on the top, 
only genes mutated more than 5% of the cohort are shown. The heatmap in the middle describes the presence 
of mutation in each of eight biological pathways (defined by TCGA). In the bottom, brief patient characteristics 
and notable cytogenetic information of each patient is shown.
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Among them, 15 mutations were from the 9 relapsed patients and 31 mutations were from the 23 non-relapsed 
patients. When comparing the frequency of mutation clearance, we did not find significant differences between 
the patients who relapsed and did not relapse (12/27 mutations in relapsed patients vs. 41/72 mutations in non-
relapsed patients, p = 0.27). In addition, complete clearance rate in relapsed patients was comparable to that 
in non-relapsed patients (5/14 relapsed patients vs. 12/35 non-relapsed patients, P = 0.92). We then assessed 
clinical relevance of mutation clearance from various perspectives. Using 0.3% as a cut-off for allelic burden at 
remission, we did not find association of mutation clearance at 0.3% (MC03) with OS (HR 0.63, [0.20–1.97], 
p = 0.43) or with relapse risk (HR 0.84, [0.23–3.04], P = 0.80) (Fig. 2c,d). We have applied various other cut-offs 
but observed likewise patterns of no correlation with OS. For example, complete mutation clearance also did 
not any association with OS or relapse risk (HR 0.39, [0.11–1.36], p = 0.14 and HR 0.88, [0.32–2.47], p = 0.81). 
Among the 29 patients with RUNX1-RUNX1T1 with available qPCR data, 20 patients were MRD-positive by 
Figure 2.  Dynamics and clinical relevance of somatic mutations during remission and its relationship with 
fusion transcript from serial sampling. (a) Reduction of allelic burden from diagnosis to CR. Ninety-nine 
mutations detected from 49 patients (4 patients without mutations at diagnosis) showed mean reduction rate 
of 99.1%. (b) Persistent allelic burden at CR and their association with relapse status. X-axis indicates VAF at 
initial diagnosis and Y-axis indicates VAF at CR. Red dots indicate mutations from relapsed patients and blue 
dots indicate mutations from non-relapsed patients. (c) Achievement of MC03 does not affect overall survival 
(HR 0.63, [0.20–1.97], P = 0.43) nor (d) relapse risk (HR 0.76, [0.23–3.04], P = 0.68). Among patients who were 
MRD-positive, achievement of MC03 does not affect (e) overall survival (HR 0.73, [0.15−3.52], P = 0.69) and 
(f) cumulative incidence of relapse. (HR 0.85, [0.14−5.14], P = 0.86). (g) Relationship between the reduction 
level of t(8;21) fusion transcript (measured by qPCR, y-axis) and VAFs (measured by NGS, x-axis). Each dot 
indicates a mutation, not a patient. Reduction level for both t(8;21) fusion transcript and VAFs were measured 
from the initial diagnosis to complete remission. Allelic burden was measured for each mutation and t(8;21) 
fusion transcript level assigned for each mutation is from the patient carrying the mutation. Color indicates 
their cluster assignment (cluster 1 as purple, cluster 2 as green, and cluster 3 as orange). Reduction level of allelic 
burden of cluster 1 and cluster 2 mutations is comparable to reduction level of mutation carriers’ t(8;21) fusion 
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qPCR at CR. Nine patients who achieved MRD-negative also achieved MC03 as well. When considering only 
MRD-positive patients, achievement of MC03 did not affect OS (HR 0.73, [0.15–3.52], P = 0.69) and relapse inci-
dence (HR 0.85, [0.14–5.14], P = 0.86, Fig. 2e,f). Lastly, we assessed whether persistence of cKIT-D816mut at CR is 
associated with higher risk of relapse, but complete clearance of KIT-D816mut also did not affect OS and relapse 
incidence (HR 0.94, [0.16–5.18], P = 0.94 and HR 0.58, [0.16–2.09], P = 0.40, respectively, Fig. S2).
We next assessed the relationship between dynamics of the fusion transcript and mutation events. By com-
paring reduction level of the RUNX1-RUNX1T1 fusion transcript measured by qPCR with reduction of allelic 
burden from 29 patients, we inferred the relationship between them (Fig. 2g). We defined three clusters showing 
distinct patterns. Cluster 1 consisted of mutations for which both somatic mutations and fusion transcript levels 
were detected (purple, 24 mutations from 17 patients). Cluster 2 was defined by both allelic burden and fusion 
transcripts not detected (green, 6 mutations from 3 patients). Cluster 3 was a group in which only somatic muta-
tions were not detectable (orange, 28 mutations from 20 patients). Altogether, our results confirmed that the 
reduction level of fusion transcripts is more appropriate measure to assess MRD than single nucleotide variants 
and short indels in CBF-AML.
Spectrum and dynamics of transcript expression in CBF AML from diagnosis to complete 
remission. After reads processing and removing genes with very low expression in most samples, we 
quantified expressions of 1293 genes in 90 samples (Table S7)21,22. At diagnosis, we identified 297 differentially 
expressed genes (DEGs) between t(8;21) AML and inv(16) AML (Fig. 3a,b, Table S7, Fig. S3). Notably, RUNX1T1 
was the most differentially expressed gene between two subtypes, where t(8;21) AML expresses it nearly 4300 
times higher than inv(16) AML (Fig.  3b). On the other hand, expression of MYH11 was 6.3 fold higher in 
inv(16) AML (Fig. 3b).When paired diagnostic-CR samples for each subtype were compared, we found 402 and 
286 DEGs in t(8;21) and inv(16) AML, where 200 genes were shared (Fig. S3, colored region). These 200 shared 
DEGs including PD1, PD-L1, PD-L2, and CTLA4 were enriched in Kyoto Encyclopedia of Genes & Genomes 
(KEGG) terms related to immune response such as cytokine-cytokine receptor interaction (q < 2.2e−5), allograft 
rejection (q < 0.02) and, graft − versus − host disease (q < 0.02) (Figs. S3–S5, Table S8)23.
With respect to fusion transcripts, in addition to the subtype-defining fusion transcripts, we detected 26 
additional fusion transcripts from 18 patients (9 inv(16) and 9 t(8;21) AML) including two recurrent fusion 
transcripts in t(8;21) AML (SLC45A3-ELK4 and CSNK1G2-JAK2) (Fig. 3c and Table S9). Six samples taken at 
relapse (all t(8;21) AML) expressed RUNX1-RUNX1T1 with breakpoints identified in their corresponding diag-
nostic samples and their transcriptome profiles were clustered with diagnostic t(8;21) AML samples (Fig. 3c). 
All CR samples were clustered together regardless of subtypes.
Feasibility of RNA sequencing ‑based fusion transcript tracking as an alternative tool for MRD 
monitoring in CBF‑AML. Subtype-defining fusion transcripts were detected in all 42 diagnostic samples. 
In every CR sample, we tracked the fusion transcript identified in their corresponding diagnostic samples. As 
expected, both RUNX1-RUNX1T1 and CBFB-MYH11 showed significant reductions in all CR samples compared 
to their corresponding diagnostic samples (P < 6.3e−05 and P < 2.2e−13, paired t-test, Fig. 4a,b). Despite low 
expression, CBFB-MYH11 was detectable in 6/19 (32%) and RUNX1-RUNX1T1 was detectable in 15/23 (65%) 
CR samples. On average, 1618 reads were mapped to RUNX1-RUNX1T1(IQR 1284–1764 reads) and 239 reads 
were mapped to CBFB-MYH11 (IQR 201–416 reads) in diagnostic samples. As the number of aligned reads were 
comparable between diagnostic and remission samples (3.01 M vs. 2.92 M reads, p = 0.19), limits of detection of 
RUNX1-RUNX1T1 and CBFB-MYH11 fusion transcripts using RNA-seq in CR samples would be approximately 
3-log (1 in 1000) and 2-log (1 in 100) reduction. Reduction level of RUNX1-RUNX1T1 measured by RNA-
seq showed positive correlation with the reduction level measured by qPCR (Pearson’s Rho = 0.74, P < 5.4e−05, 
Fig. 4c and Table S10). Three-log or deeper reduction of RUNX1-RUNX1T1 was able to predict relapse incidence 
(HR 0.22 [0.03–1.69], p = 0.14). When compared with qPCR-based MRD, RNA-seq-based MRD showed com-
parable performance in terms of sensitivity, specificity, positive/negative predictive value using 3-log reduction 
as a cut-off in RUNX1-RUNX1T1 AML (Table  S11). qPCR data were not available for CBFB-MYH11 AML. 
Survival analyses using mutation profile identified cKIT-D816mut at diagnosis as an adverse prognostic factor 
for long-term outcome. Just as cKIT-D816mut was all detected with high allelic burden using DNA-seq, it was 
reliably detected using RNA-seq as well (allelic burden ranges 20.8–46.4% in DNA-seq and 32.7–73.4% in RNA-
seq) (Table S12).
Prognostic modeling utilizing RNA‑sequencing data in CBF‑AML. As RNA-seq can reliably meas-
ure reduction levels of fusion transcripts and detect high-risk mutations (i.e. cKIT-D816mut), we attempted to 
build a prognostic model using decision tree analysis incorporating genetic features obtained from RNA-seq. 
Decision tree analysis identified three distinct subgroups of RUNX1-RUNX1T1 AML on the basis of reduction 
in the level of RUNX1-RUNX1T1 transcript and mutation profile (Fig. 5a). Consistent with previous studies, 
3-log or deeper reduction of RUNX1-RUNX1T1 transcript was the most significant prognostic factor (low risk 
group)14,15. The algorithm further divided the patients who failed to achieve 3-log reduction according to the 
presence of cKIT-D816 mutation at diagnosis (intermediate and high-risk groups). For three defined groups, 
2-year OS rates were 87%, 74%, and 33% (p = 0.08, Fig. 5b) and 2-year relapse incidence rates were 13%, 42%, 
and 67% (p = 0.048, Fig. 5c).
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Discussion
Current study demonstrated that RNA-seq can measure reduction levels of RUNX1-RUNX1T1 and CBFB-MYH11 
from diagnosis to CR. RUNX1-RUNX1T1 reduction levels measured by qPCR and RNA-seq showed high cor-
relation and concordance. The prognostic mutation (i.e. KIT-D816mut) was reliably detected in both DNA and 
RNA-seq data. Solely using information from RNA-sequencing, we built a prognostic model that can predict 
long-term outcome for t(8;21) AML patients. On the other hand, complete clearance of secondary genetic 
lesions (i.e. single nucleotide variants and short indels) including KIT-D816mut alone was not associated with 
better long-term outcomes and mutation persistence at low level did not provide prognostic power in addition 
to reduction level of the fusion transcripts. Altogether, our data and analyses suggest the clinical utility of RNA-
seq as a method to detect MRD in CBF-AML and potentially in other fusion-driven hematologic malignancies.
Leveraging on paired-diagnosis-CR samples, we assessed the clinical relevance of residual genetic lesions at 
remission in CBF-AML. Although several studies demonstrated clinical relevance of residual allelic burden in 
non-CBF-AML, none of the studies thus far focused on CBF-AML3–7. To the best of our knowledge, transcrip-
tome along with mutation profile on paired diagnostic-CR samples have not been investigated in CBF-AML. 
By tracking junctions identified in corresponding diagnostic samples, we were able to quantify the level of 
Figure 3.  Spectrum and dynamics of targeted transcriptome in 42 CBF-AML patients. (a) Hierarchical 
clustering of 297 differentially expressed genes as well as summary of recurrent gene fusions. (b) Comparison of 
RNA expression between t(8;21) AML and inv(16) AML where RUNX1T1 is the most differentially expressed 
genes between two related AML subtypes. (c) Principal component analyses reveal that two subtypes at 
diagnosis are distinctly clustered, whereas CR samples are clustered regardless of their subtype. In addition, 
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RUNX1-RUNX1T1 and CBFB-MYH11 in CR samples. The level of RUNX1-RUNX1T1 reductions measured by 
RNA-seq was highly correlated with qPCR result (Pearson’s Rho = 0.74, p < 5.4e−05). RUNX1-RUNX1T1 was 
detectable in 15 samples by both techniques and in 6 samples only by qPCR. In 2 samples, RUNX1-RUNX1T1 
was undetectable by neither method. qPCR was more sensitive at detecting trace amount of RUNX-RUNX1T1 
compared to RNA-seq at the sequencing coverage in our study (avg. = 2.98 M mapped reads per sample). How-
ever, we believe that these obstacles can likely to be overcome by achieving deeper sequencing depth as well as 
more tailored sequencing strategies. CBFB-MYH11 was only detectable in 6/19 CR samples at the sequencing 
depth used in current study and qPCR results were not available for comparison. Future studies on CBFB-MYH11 
cohort with deeper sequencing depth and comparative analyses with qPCR remain to be investigated.
With respect to single nucleotide variants and short indels, allelic burden of all mutations showed significant 
reduction from diagnosis to CR (ranges from 86.2 to 100%). At CR, only 5 mutations out of 99 mutations (2 
in TET2, 1 in JAK3, U2AF1, and ASXL1 each) were observed with a VAF above 1%. This mutation clearance 
level is higher than what was reported in non-CBF-AML3,4. This could be due to differences in mutation profile 
between CBF and non-CBF-AML. Klco et al. only included intermediate and poor risk AML patients and most 
frequently persistent mutations were in DNA methylation or clonal hematopoiesis-associated genes (DNMT3A, 
TET2, IDH1/2)3. In CBF-AML, those genes are much less commonly mutated. Incorporation of mutation dynam-
ics with RUNX1-RUNX1T1 fusion transcript reduction level showed that reduction of mutation burden from 
Figure 4.  Tracking of RUNX1-RUNX1T1 and CBFB-MYH11. Both fusion transcripts are detected reliably at 
diagnosis and show significant reduction at CR (P < 2.2e−13 and P < 6.3e−05, (a,b). (c) Comparison of RUNX1-
RUNX1T1 reduction levels measured by qPCR and RNA-seq. Results from qPCR and RNA-seq show positive 
correlation (Pearson’s Rho = 0.74, P < 5.4e−05).
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Figure 5.  A prognostic model based on genetic features measured by RNA-sequencing. (a) A prognostic model 
using clinical and genetic information obtained from RNA-seq. Two variables were selected; 1. 3-log or deeper 
reduction of RUNX1-RUNX1T1 transcript level and 2. presence of cKIT-D816 mutation at diagnosis. Based 
these two factors, the algorithm identified three subgroups. (b) Overall survival and (c) cumulative incidence of 
relapse based on the defined risk groups.
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diagnosis to CR is deeper than or equal to the reduction of RUNX1-RUNX1T1 fusion transcript. This re-confirms 
that complete clearance of allelic burden (i.e. secondary lesion) during remission does not guarantee eradication 
of leukemic cells, but deeper reduction of primary lesion (i.e. fusion transcript) is a more appropriate surrogate 
marker for predicting relapse in CBF-AML. In addition to the assessment of the entire cohort with available 
CR samples, we also showed that residual allelic burden did not further stratify high risk patients among MRD-
positive patients. This result indicates that DNA-based MRD detection, only targeting secondary lesions does 
not provide additional prognostic power in addition to reduction level of the fusion transcripts in CBF-AML.
Consistent with previous studies, mutation profiles of two CBF-AML subtypes were  different24–26. For exam-
ple, members of the cohesin complex and chromatin modifiers including ASXL2 were nearly exclusively mutated 
in RUNX1-RUNX1T1 AML. Genes associated with activated signaling such as KIT, N/KRAS, CBL, and FLT3 
were frequently mutated in both subtypes. Survival analyses showed that KIT-D816mut was an adverse prognostic 
factor. As shown in Lavallée et al.27, the pattern of transcript expressions at diagnosis further distinguished these 
two related-subtypes of AML. CR samples were clustered regardless of their subtypes. We noticed that there are 
nine genes that are differentially expressed in CR samples depending on their AML subtypes. However, all nine 
genes were differentially expressed in at least one of three-way comparisons and this is likely due to the residual 
leukemia cells in CR samples.
There are several limitations in our study. First, the cohort size was relatively small, and the prognostic model 
developed using the current cohort could not be validated using an independent cohort. Second, the experi-
mental setting of RNA sequencing utilized in this study such as the gene panel, amount of total RNA used, and 
sequencing depth was not optimized for MRD purposes. For example, detection of CBFB-MYH11 using RNA-
seq in CR samples requires experimental optimizations to be compatible with qPCR. Lastly, as some of fusion 
calls were only supported by few reads, further validation using alternative techniques such as qPCR should be 
performed to validate them.
Altogether, the current study demonstrates that RNA-seq can be utilized to monitor RUNX1-RUNX1T1 and 
CBFB-MYH11 level during remission in CBF-AML. Combining all of these supporting evidences, our data and 
analyses confirmed that the reduction level of fusion transcripts and baseline characteristics at initial diagnosis 
are the most important genetic features in CBF-AML when predicting long-term outcome and they provide 
complementary prognostic information. On the other hand, residual allelic burden of secondary lesion at CR 
measured by DNA-seq alone does not provide clinically relevant information in addition to those two genetic 
features. We also showed that a single assay of RNA-seq can be used to stratify RUNX1-RUNX1T1 AML patients 
into three distinct risk groups according to their long-term prognosis. Our findings warrant prospective studies 
with larger cohorts on gene rearrangement-driven hematologic malignancies utilizing more tailored sequenc-
ing strategies.
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